GSK3B and progressive supranuclear palsy: Two phase II clinical trials with the GSK‐3β inhibitor, Tideglusib, showed no clinical benefits in Alzheimer's disease (Lovestone et al, 2015) and progressive supranuclear palsy (Tolosa et al, 2014).